Liver Cancer Program: News & Events
See Our Upcoming Seminars
Focus Area: Early Detection, Population Studies
A new blood test that may improve liver cancer screening
NCI Press Release, June 11, 2020
LCP scientists have developed a new test that can help identify people who are likely to develop hepatocellular carcinoma (HCC), the most common form of liver cancer. This method uses a simple blood test to check for the patient’s previous exposure to certain viruses. Read more...
Focus Area: Early Detection, Population Studies
Dr. Wang discusses a new blood test to identify those likely to develop liver cancer
CancerNetwork, July 14, 2020
In this interview with CancerNetwork, Xin Wei Wang, Ph.D., discusses the clinical utility of a new blood test and how it could potentially change liver cancer diagnoses moving forward. View interview...
Focus Area: Treatment
Clinical trial to determine whether antibiotics can boost immune response in treating liver cancer
CCR News, May 14, 2019
In this clinical trial, patients with liver cancer will be given antibiotics, along with two drugs, to explore whether manipulating microbes within the gut of a patient can boost their immune system’s response to the disease. Read more...
Focus Area: Treatment
Clinical trial finds combination therapy effective for some biliary cancer patients
CCR News, January 28, 2019
An early-phase clinical trial has established that the immunotherapy agent tremelimumab, combined with microwave ablation therapy, is safe for patients with advanced biliary tract cancer (BTC). Read more...
Focus Area: Prognosis
Dr. Budhu discusses potential molecular markers in liver cancer
OncLive, October 11, 2019
In this interview with OncLive, Anuradha S. Budhu, Ph.D., discusses using molecular features as predictive markers in liver cancer. View interview...
What's Next in Liver Cancer Research
October 30, 2018
Drs. Budhu, Greten and McGlynn join Twitter Live to discuss ‘What’s Next in Liver Cancer Research’.
Focus Area: Prognosis
A mosaic of liver tumor cells
Milestones 2020
Tumors are complex communities of cells. Cancerous cells intermingle with noncancerous cells, and additional diversity arises as a tumor’s cancer cells divide and acquire new genetic mutations. Now, LCP scientists have discovered that the extent of cellular diversity within a tumor may shape its response to immune checkpoint inhibitors in patients with liver cancer. Read more...
Focus Area: Treatment
Liver tumors link to the microbiome
CCR Milestones 2019
LCP scientists show how bacteria that live in the gut can hinder the immune system’s ability to control tumors in the liver. Read more...
Focus Area: Diagnosis
Selective CD4+ T Cell Loss Promotes Liver Cancer Development
CCR Milestones 2017
LCP research identified a novel link between obesity-induced lipid accumulation and selective CD4+ T cell loss, which impairs tumor immunity and enhances liver cancer development. These findings shed light on how metabolic changes promote NAFLD (non-alcoholic fatty liver disease)-related liver cancer. Read more...
Seminars
2021 Seminars (virtual)
(virtual seminars are held at 2PM EST unless otherwise noted)
February 26 (12:00-1:00PM)
Xin Wei Wang, PhD., Co-Director, NCI CCR Liver Cancer Program and Deputy Chief, Laboratory of Human Carcinogenesis
CCR Grand Rounds: Defining Liver Cancer Heterogeneity-New Challenges and Opportunities
Join by WebEx; Join by phone: 1-650-479-3207
March 25 Jill Koshiol, PhD, Senior Investigator, Infections and Immunoepidemiology Branch, DCEG
April 22 Bernadette Redd, MD, Staff Clinician, Radiology and Imaging Sciences, NIH
May 20 Hao Zhu, MD, Associate Professor, Children's Research Institute at UT Southwestern
June 21 Jesper Andersen, MSc, PhD, Associate Professor, University of Copenhagen (*10am EST)
September 30 Eli Pikarsky, MD, PhD, Associate Professor, The Hebrew University of Jerusalem (*10am EST)
Previous Seminars
News Archive
To view a list of past seminars and other events, visit News and Events Archive.